Pfizer gains generics, injectables in InnoPharma buy
This article was originally published in Scrip
Executive Summary
Pfizer will pay $225m in upfront cash and up to $135m in milestone fees to buy InnoPharma, a private Piscataway, New Jersey-based company with 10 approved generic medicines, 19 more under US FDA review, and 30 injectable and ophthalmic products under development.